论文部分内容阅读
目的:比较胺碘酮与普罗帕酮对急性心肌梗死患者伴心房颤动的临床疗效和安全性。方法:选取2015年1月—2016年11月间收治的心肌梗死伴心房颤动患者108例资料,将其随机分为对照组和观察组(每组54例);对照组患者给予普罗帕酮治疗,观察组患者给予胺碘酮治疗,比较两组患者治疗后的总有效率和不良反应的发生率。结果:观察组患者治疗后的总有效率为90.74%高于对照组为72.22%(P<0.05),不良反应的发生率为7.41%低于对照组为25.93%(P<0.05)。结论:胺碘酮用于治疗急性心肌梗死伴心房颤动患者的疗效优于普罗帕酮,且用药期间不良反应的发生率较低。
Objective: To compare the clinical efficacy and safety of amiodarone and propafenone in patients with acute myocardial infarction with atrial fibrillation. Methods: A total of 108 patients with myocardial infarction and atrial fibrillation who were admitted between January 2015 and November 2016 were selected and randomly divided into control group and observation group (54 cases in each group). Patients in the control group were treated with propafenone , The observation group was given amiodarone treatment, the total effective rate and the incidence of adverse reactions after treatment in both groups were compared. Results: The total effective rate of observation group after treatment was 90.74% higher than that of the control group (72.22%, P <0.05). The incidence of adverse reactions was 7.41%, which was lower than that of the control group (25.93%, P <0.05). Conclusions: Amiodarone is superior to propafenone in the treatment of patients with acute myocardial infarction and atrial fibrillation and has a lower incidence of adverse reactions during the course of treatment.